HER2-Low Breast Cancer: DESTINY or Good Science?

#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024Подробнее

HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review ConferenceПодробнее

Evolving and Emerging Trends in HER2 Classification and Reporting in Breast CancerПодробнее

ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...Подробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

The Science of HER2-low Breast Cancer and Implications for the Pathology TeamПодробнее